Your browser doesn't support javascript.
loading
Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee, Fiona; Hernandez, Dennis; Zhou, Nannan; Yu, Fei; Ueland, Joseph; Monikowski, Aaron; Chayama, Kazuaki; Toyota, Joji; Izumi, Namiki; Yokosuka, Osamu; Kawada, Norifumi; Osaki, Yukio; Hughes, Eric A; Watanabe, Hideaki; Ishikawa, Hiroki; Kumada, Hiromitsu.
Affiliation
  • McPhee F; Bristol-Myers Squibb, Wallingford, CT, USA. fiona.mcphee@bms.com.
Antivir Ther ; 19(5): 479-90, 2014.
Article in En | MEDLINE | ID: mdl-24448487
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Plantas_medicinales Main subject: Antiviral Agents / Polyethylene Glycols / Ribavirin / Interferon-alpha / Hepacivirus / Hepatitis C, Chronic / Genotype / Imidazoles Type of study: Clinical_trials Language: En Journal: Antivir Ther Year: 2014 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Plantas_medicinales Main subject: Antiviral Agents / Polyethylene Glycols / Ribavirin / Interferon-alpha / Hepacivirus / Hepatitis C, Chronic / Genotype / Imidazoles Type of study: Clinical_trials Language: En Journal: Antivir Ther Year: 2014 Type: Article Affiliation country: United States